Abstract: The flag holding device is a mounting device that is adapted to receive a flag pole. The flag holding device is inserted into the ground. The flag holding device comprises a post and a sign. The sign is attached to the post. The post is inserted into the ground. The sign is configured to receive and hold a flag pole to which a flag is attached.

Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare Plasmodium falciparum epitopes, and to develop epitope-based vaccines directed towards malaria. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of malaria. In particular, this application discloses isolated peptides comprising oligopeptides, for example the oligopeptides LLACAGLAY, FLIFFDLFLV, FMKAVCVEV, VLAGLLGNV, GLIMVLSFL, KILSVFFLA, GLLGNVSTV, VLLGGVGLVL, ILSVSSFLFV, QTNFKSLLR, LACAGLAYK, ALFFIIFNK, LLACAGLAYK, HVLSHNSYEK, FILVNLLIFH, FQDEENIGIY, PSDGKCNLY, YYIPHQSSL, FYFILVNLL, KYLVIVFLI and KYKLATSVL, or isolated peptides conjugated with T helper peptides that are used as antigens in epitope-based vaccines to prevent and/or treat malaria.

Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare Plasmodium falciparum epitopes, and to develop epitope-based vaccines directed towards malaria. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of malaria. In particular, this application discloses isolated peptides comprising oligopeptides, for example the oligopeptide GVSENIFLK, or isolated peptides conjugated with T helper peptides that are used as antigens in epitope-based vaccines to prevent and/or treat malaria.

Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HPV infection.

Abstract: The invention relates to the field of biology. In particular, the invention relates to a method and system for designing optimized multi-epitope vaccines having selected combinations of amino acid insertions at the junctions of the multi-epitope constructs so as to minimize the number of junctional epitopes and provide vaccines with increased immunogenicity.

Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HPV infection.

Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare prostate cancer-associated antigent epitopes, and to develop epitope-based vaccines directed towards prostate tumors. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of cancer.

Abstract: A composition or vaccine composition comprising at least one peptide that has less than 600 contiguous amino acids having 100% identity to a native sequence of CEA, HER2/neu, MAGE2, MAGE3, or p53, the peptide further comprising at least one epitope selected from Table 6.